Addiction Medicine Updates
Latest News & Upcoming Events
Dr. Jana Burson discusses how many physicians still get confused about how to treat acute pain in patients who are prescribed buprenorphine products for opioid use disorder. In her blog, she explains that while buprenorphine products (whether Suboxone, Subutex,...
The North Carolina Department of Health and Human Services and the Department of Public Safety are partnering to create a new medication-assisted treatment (MAT) program to reduce the overdose-related deaths of people with an opioid disorder who are re-entering their...
A new study reveals marked health disparities in who does and doesn’t get medication assisted treatment for opioid addiction. According to data from 2012 to 2015 analyzed by researchers from the University of Michigan and VA Ann Arbor Healthcare System, for every...
As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.
The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.
Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.
CONTINUING MEDICAL EDUCATION: This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.
For More Information and FREE training and educational resources on Medication Assisted Treatment –Providers’ Clinical Support System for Medication Assisted Treatment (PCSS-MAT) visit www.pcssnow.org.
PCSS is a collaborative effort led by the American Academy of Addiction Psychiatry (AAAP) in partnership with the: American Osteopathic Academy of Addiction Medicine (AOAAM); Addiction Technology Transfer Center (ATTC); American Academy of Family Physicians (AAFP); American Academy of Neurology (AAN); American Academy of Pain Medicine (AAPM); American Academy of Pediatrics (AAP); American College of Emergency Physicians (ACEP); American College of Physicians (ACP); American Dental Association (ADA); American Medical Association (AMA); American Psychiatric Association (APA); American Psychiatric Nurses Association (APNA); American Society of Addiction Medicine (ASAM); American Society for Pain Management Nursing (ASPMN); Association for Medical Education and Research in Substance Abuse (AMERSA); International Nurses Society on Addictions (IntNSA); National Association of Community Health Centers (NACHC); National Association of Drug Court Professionals (NADCP), and the Southeast Consortium for Substance Abuse Training (SECSAT).
Funding for this initiative was made possible (in part) by grant nos. 5U79TI026556-02 and 3U79TI026556-02S1 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Opioid dependence is epidemic in the United States. While progress has been made in training providers, the gap in providing effective treatment of opioid use disorders continues to widen, moving beyond heroin addicted individuals to a much larger and diverse segment of the population. This increase is predominantly due to an alarming increase in addiction to prescription opioid analgesic medications. Buprenorphine, the most recent addition to the pharmacotherapies available to treat opioid dependence, is novel among the opioid pharmacotherapies because of its partial agonist properties. It has been placed on Schedule III and is available by prescription from a physician’s office-based practice.
Recognizing the impact of this addiction, as well as learning how to treat opioid use disorders, are important steps in combating this ever growing medical problem. To obtain the waiver to prescribe, providers are required to take specialized training. PCSS-MAT uses the Half-and-Half format (first, 4.25 hours of face-to-face training with an instructor, followed by 3.75 hours of on-your-own-training that must be completed along with a post test). This training meets the requirements for physicians; however additional training is required for advanced practice providers. The training focuses on specifics of treating patients with opioid use disorders in office-based settings and clinical vignettes to help trainees think through “real life” experiences in opioid use disorders treatment. Once the waiver training is completed in full, participants will receive a CME certificate of attendance from AAAP.
This program includes up to 2.0 hours of controlled substances content. Per NCAC rules: As of July 1, 2017, all physicians (other than residents), physician assistants, nurse practitioners, podiatrists, and dentists who prescribe controlled substances must satisfy the controlled-substance prescribing CE requirements as set forth by their licensing boards. Requirements vary by discipline and board.
The program is recommended for prescribers in primary care, emergency medicine, pain management, psychiatric, HIV, and addiction medicine. (Not a prescriber? CLICK HERE)
- Review addiction treatment in office-based practices
- Discuss the pharmacological treatments of opioid use disorder
- Determine what medical record documentation must be followed
- Discuss the process of buprenorphine induction as well as stabilization and maintenance techniques
- Describe how to take a patient history and evaluation
- Review safety concerns and drug interactions
Opioid addiction is a chronic, relapsing brain disease that affects millions of Americans and produces a tremendous burden on the healthcare system. In 2002, U.S. physicians gained the opportunity to treat opioid-addicted patients with buprenorphine in primary care settings, commonly referred to as office-based opioid treatment (OBOT). OBOT has been shown to be effective in primary care settings and impacts public health through the reduction of opioid use, opioid overdose mortality and transmission of infectious diseases. However, it remains underutilized.
One consistently cited barrier preventing OBOT expansion is lack of adequate clinical support given the additional needs for patient monitoring. Successful medication-assisted treatment (MAT) requires a team-based approach just like treatment for other chronic diseases. In addition, treatment is more effective when providers can use a trauma-informed and gender-responsive treatment plan.
The goal of this companion program to the AAAP Clinical Support System: Buprenorphine Office-Based Treatment for Opioid Use Disorders (The “Half and Half” Course) is to increase the comfort level and expertise of the healthcare team by outlining a team approach, trauma-informed interventions, gender-responsive care, and recommendations for implementation of buprenorphine OBOT.
Nurses, mental health professionals including substance abuse counselors, social workers, psychologists, marriage and family therapists, school counselors, practice managers, program administrators, medical assistants, care managers and coordinators and other professionals interested in this subject.
- Describe the presented framework of office-based opioid treatment (OBOT) including practice changes, medications used, psychosocial services and integration/coordination components
- Utilize evidence-based interventions that are trauma-informed and gender-responsive to treat persons with substance use disorders
- Define the roles of an effective practice team, including primary care and behavioral health clinicians, working together with patients and families, and using a systematic and cost-effective approach to provide patient-centered care for opioid and other substance use disorders
- Increase medical and behavioral health professionals’ receptivity and capability to work collaboratively as they evaluate and manage opioid and other substance use disorders using SBIRT (screening, brief intervention and referral to treatment)
- List key components of evidence-based and effective OBOT